Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Short-term Investments (2016 - 2026)

Anika Therapeutics has reported Short-term Investments over the past 13 years, most recently at $25.8 million for Q1 2026.

  • Quarterly Short-term Investments rose 17.2% to $25.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $25.8 million through Mar 2026, up 17.2% year-over-year, with the annual reading at $23.7 million for FY2025, 0.41% changed from the prior year.
  • Short-term Investments was $25.8 million for Q1 2026 at Anika Therapeutics, up from $23.7 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $36.7 million in Q2 2023 and troughed at $22.0 million in Q1 2025.
  • The 5-year median for Short-term Investments is $29.3 million (2022), against an average of $29.1 million.
  • Year-over-year, Short-term Investments crashed 31.46% in 2025 and then rose 17.2% in 2026.
  • A 5-year view of Short-term Investments shows it stood at $34.6 million in 2022, then dropped by 23.87% to $26.4 million in 2023, then fell by 10.49% to $23.6 million in 2024, then increased by 0.41% to $23.7 million in 2025, then rose by 8.77% to $25.8 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Short-term Investments are $25.8 million (Q1 2026), $23.7 million (Q4 2025), and $22.2 million (Q3 2025).